Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study

CONCLUSION: Our results from clinical practice suggest that RDV and SARS-CoV-2 mAb therapies elicit worse outcomes in hematological patients than those reported for high-risk population in clinical trials.PMID:37656351 | DOI:10.1007/s43440-023-00519-8

Source: Pharmacological Reports - September 1, 2023 Category: Drugs & Pharmacology Authors: Juan Vicente-Valor Carmen Rodr íguez-González Mar ía Ferris-Villanueva Esther Chamorro-de-Vega Rosa Romero-Jim énez Daniel G ómez-Costas Sergio Herrero-Bermejo Francisco Tejerina-Picado Santiago Osorio-Prendes Gillen Oarbeascoa-Royuela Ana Herranz-Al Source Type: research